JPI-289 clinical trials
Also written JPI-289.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses JPI-289 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- JPI-289
- 2
Studies by the year they started
3 studies that test it; most in 2013 (1)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of PARP inhibitors source
Studies
Open first, then newest update. How each study uses JPI-289 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic StrokeStatus unknownPhase 2Jeil Pharmaceutical Co., Ltd.NCT03062397Written as JPI-289 Low-doseHow we know
- The Evaluation of Safety, Tolerability and Pharmacokinetics of Stroke Targeting Drug in Healthy VolunteersCompletedPhase 1Jeil Pharmaceutical Co., Ltd.NCT01983358Written as JPI-289How we know
- The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male VolunteersCompletedPhase 1Jeil Pharmaceutical Co., Ltd.NCT02396069Written as JPI-289How we know